Yttrium Y 90 Carbon Microspheres NRT6003 clinical trials
How each study uses Yttrium Y 90 Carbon Microspheres NRT6003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Yttrium Y 90 Carbon Microspheres NRT6003 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Chengdu New Radiomedicine Technology Co. LTD. (2) · Second Affiliated Hospital of Guangzhou Medical University (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Yttrium Y 90 Carbon Microspheres NRT6003, phase 3 first.
- Oct 2027Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSpherePhase 3 · Chengdu New Radiomedicine Technology Co. LTD.
Studies
Open first, then newest update. How each study uses Yttrium Y 90 Carbon Microspheres NRT6003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular CarcinomaNot yet recruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT07657273Written as NRT6003 Injection
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingPhase 3Chengdu New Radiomedicine Technology Co. LTD.NCT06900543Written as NRT6003 Injection
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedPhase 1Chengdu New Radiomedicine Technology Co. LTD.NCT06310590Written as NRT6003 Injection